Supplementary Table 4 from Phase Ib/II Study of a Liposomal Formulation of Eribulin (E7389-LF) plus Nivolumab in Patients with Advanced Solid Tumors: Results from Phase Ib
openalex(2023)
摘要
Supplementary Table 4. Pharmacokinetic Parameters After Administration of E7389-LF
查看译文
关键词
eribulin,liposomal formulation,advanced solid tumors,nivolumab,solid tumors
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要